Kyverna Therapeutics, Inc. (KYTX)
| Market Cap | 657.51M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -60.37M |
| Shares Out | 43.12M |
| EPS (ttm) | -89.61 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 459,143 |
| Open | 14.86 |
| Previous Close | 15.03 |
| Day's Range | 14.81 - 16.45 |
| 52-Week Range | 13.96 - 30.60 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 39.50 (+162.81%) |
| Earnings Date | May 16, 2024 |
About KYTX
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for KYTX stock is "Buy." The 12-month stock price forecast is $39.5, which is an increase of 162.81% from the latest price.
News
Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases
Poster #14-006 describes the first successful treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR-T cells Kyverna to host a conference ca...
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med
Two patients were treated with KYV-101, a fully human anti-CD19 CAR T-cell product candidate, in Germany as part of a named patient program after failure to respond to conventional therapies The treat...
Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results
Advanced clinical development in two broad areas of autoimmune disease: rheumatology and neurology Strong balance sheet, bolstered by recent public offering, expected to fund operations into 2026 EMER...
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis
The Investigator-Initiated Trial will assess the safety, tolerability, and clinical activity of KYV-101, a fully human anti CD19 CAR T-cell therapy in up to 12 study participants The clinical study wi...
Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
EMERYVILLE, Calif. , Feb. 12, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients s...
Gilead-backed Kyverna Therapeutics valued at $1.4 bln in stellar debut
Shares of Kyverna Therapeutics jumped 55.7% in their market debut on Thursday, giving the biopharmaceutical company that is backed by Gilead Sciences a market capitalization of $1.4 billion.
Kyverna Therapeutics to raise $319 million in upsized IPO
Gilead-backed Kyverna Therapeutics on Wednesday said it will raise $319 million at a valuation of $898.1 million in an upsized U.S. initial public offering (IPO).
Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering
EMERYVILLE, Calif. , Feb. 7, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients su...
Gilead-backed Kyverna Therapeutics aims for $857.3 mln valuation in upsized IPO
Kyverna Therapeutics expects up to $857.3 million valuation in its U.S. initial public offering (IPO), the biotechnology company said on Tuesday as it raised its offering.
Kyverna Therapeutics targets up to $711 mln valuation in US IPO
Biotechnology company Kyverna Therapeutics said on Thursday it was aiming for a market valuation of up to $711 million in its U.S. initial public offering (IPO).
Autoimmune disease biotech Kyverna Therapeutics files for a $100 million IPO
Kyverna Therapeutics, a Phase 2-ready biotech developing cell therapies for autoimmune diseases, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.
Kyverna Therapeutics IPO Registration Document (S-1)
Kyverna Therapeutics has filed to go public with an IPO on the NASDAQ.
Alto, Kyverna Join Growing Number of Biotech IPO Filings in 2024
Alto Neuroscience and Kyverna Therapeutics are following in the footsteps of CG Oncology, Metagenomi and Arrivent in seeking initial public offerings this year.
Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Myasthenia Gravis
Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for...